OBJECTIVE: The purpose of this study was to determine if treatment of pregnant women with Chlamydia trachomatis infection would lower the incidence of preterm delivery and/or low birth weight. METHODS:Pregnant women between the 23rd and 29th weeks of gestation were randomized in double-blind fashion to receive either erythromycin 333 mg three times daily or an identical placebo. The trial continued until the end of the 35th week of gestation. RESULTS: When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7). At the sites with high persistence of C. trachomatis in the placebo-treated women, low birth weight infants occurred in 9 (8%) of 114 erythromycin-treated and 18 (17%) of 105 placebo-treated women (P = 0.04) and delivery <37 weeks occurred in 15 (13%) of 115 erythromycin-treated and 18 (17%) of 105 placebo-treated women (P = 0.4). CONCLUSIONS: The results of this trial suggest that the risk of low birth weight can be decreased by giving erythromycin to some women with C. trachomatis. Due to the high clearance rate of C. trachomatis in the placebo group, these data do not provide unequivocal evidence that erythromycin use in all C. trachomatis-infected women prevents low birth weight.
RCT Entities:
OBJECTIVE: The purpose of this study was to determine if treatment of pregnant women with Chlamydia trachomatis infection would lower the incidence of preterm delivery and/or low birth weight. METHODS: Pregnant women between the 23rd and 29th weeks of gestation were randomized in double-blind fashion to receive either erythromycin 333 mg three times daily or an identical placebo. The trial continued until the end of the 35th week of gestation. RESULTS: When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7). At the sites with high persistence of C. trachomatis in the placebo-treated women, low birth weight infants occurred in 9 (8%) of 114 erythromycin-treated and 18 (17%) of 105 placebo-treated women (P = 0.04) and delivery <37 weeks occurred in 15 (13%) of 115 erythromycin-treated and 18 (17%) of 105 placebo-treated women (P = 0.4). CONCLUSIONS: The results of this trial suggest that the risk of low birth weight can be decreased by giving erythromycin to some women with C. trachomatis. Due to the high clearance rate of C. trachomatis in the placebo group, these data do not provide unequivocal evidence that erythromycin use in all C. trachomatis-infectedwomen prevents low birth weight.
Authors: D A Eschenbach; R P Nugent; A V Rao; M F Cotch; R S Gibbs; K A Lipscomb; D H Martin; J G Pastorek; P J Rettig; J C Carey Journal: Am J Obstet Gynecol Date: 1991-03 Impact factor: 8.661
Authors: M A Klebanoff; J A Regan; A V Rao; R P Nugent; W C Blackwelder; D A Eschenbach; J G Pastorek; S Williams; R S Gibbs; J C Carey Journal: Am J Obstet Gynecol Date: 1995-05 Impact factor: 8.661
Authors: Ronald F Lamont; Chia-Ling Nhan-Chang; Jack D Sobel; Kimberly Workowski; Agustin Conde-Agudelo; Roberto Romero Journal: Am J Obstet Gynecol Date: 2011-04-02 Impact factor: 8.661
Authors: Kristina Adachi; Jeffrey D Klausner; Jiahong Xu; Bonnie Ank; Claire C Bristow; Mariza G Morgado; D Heather Watts; Fred Weir; David Persing; Lynne M Mofenson; Valdilea G Veloso; Jose Henrique Pilotto; Esau Joao; Glenda Gray; Gerhard Theron; Breno Santos; Rosana Fonseca; Regis Kreitchmann; Jorge Pinto; Marisa M Mussi-Pinhata; Mariana Ceriotto; Daisy Maria Machado; Yvonne J Bryson; Beatriz Grinsztejn; Francisco I Bastos; George Siberry; Karin Nielsen-Saines Journal: Pediatr Infect Dis J Date: 2016-08 Impact factor: 2.129
Authors: G Ingrid J G Rours; Liesbeth Duijts; Henriette A Moll; Lidia R Arends; Ronald de Groot; Vincent W Jaddoe; Albert Hofman; Eric A P Steegers; Johan P Mackenbach; Alewijn Ott; Hendrina F M Willemse; Elizabeth A E van der Zwaan; Roel P Verkooijen; Henri A Verbrugh Journal: Eur J Epidemiol Date: 2011-05-03 Impact factor: 8.082
Authors: Jane Hitti; Pedro Garcia; Patricia Totten; Kathleen Paul; Sabina Astete; King K Holmes Journal: Sex Transm Dis Date: 2010-02 Impact factor: 2.830
Authors: Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar Journal: Cochrane Database Syst Rev Date: 2019-01-18